CEBP Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by González-Zuloeta Ladd, A. M.
Right arrow Articles by van Duijn, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by González-Zuloeta Ladd, A. M.
Right arrow Articles by van Duijn, C.
Cancer Epidemiology Biomarkers & Prevention Vol. 14, 2143-2146, September 2005
© 2005 American Association for Cancer Research

Angiotensin-Converting Enzyme Gene Insertion/Deletion Polymorphism and Breast Cancer Risk

Angela M. González-Zuloeta Ladd, Alejandro Arias Vásquez, Fakhredin A. Sayed-Tabatabaei, J.W. Coebergh, Albert Hofman, Omer Njajou, Bruno Stricker and Cornelia van Duijn

Epidemiology and Biostatistics Department, Erasmus Medical Center, Rotterdam, the Netherlands

Requests for reprints: Cornelia van Duijn, Department of Epidemiology and Biostatistics, Erasmus Medical Center, P.O. Box 1738, 3000 DR Rotterdam, the Netherlands. Phone: 31-10-408-7394; Fax: 31-10-408-9406. E-mail: c.vanduijn{at}erasmusmc.nl


   Abstract
Top
 Abstract
Introduction
 Patients and Methods
 Results
 Discussion
 References
 
Background: The renin-angiotensin system plays an important role in homeostasis and lately, its main effector, angiotensin II, has been attributed with angiogenic and growth factor actions in the breast tissue. Previous studies have shown that the insertion/deletion (I/D) polymorphism in the angiotensin-converting enzyme (ACE) gene accounts for the variability of ACE plasma concentrations. The use of ACE inhibitors and the ACE I/D polymorphism may be linked to breast cancer risk. In this study, we evaluate the relationship of the ACE I/D polymorphism with breast cancer risk in Caucasian postmenopausal women.

Methods: The ACE I/D polymorphism was genotyped in 4,117 women participants in the Rotterdam Study. Baseline information was obtained through a questionnaire. We conducted a logistic regression and survival analysis to assess the risk of breast cancer by the ACE genotype.

Results: The DD carriers showed a significantly increased risk of developing breast cancer when compared with the II carriers (odds ratio, 1.86; 95% confidence interval, 1.06-3.27; P = 0.03). This association remained after adjusting for other risk factors, including body mass index, age at menarche, age at menopause, hormone replacement therapy, and hypertension. Our survival analysis showed that the cancer-free survival was significantly reduced in DD compared with II carriers (hazard ratio, 1.80; 95% confidence interval, 1.07-3.01; P = 0.03).

Conclusions: Our results suggest that the ACE I/D polymorphism plays an important role in breast cancer risk and disease-free survival in Caucasian postmenopausal women.


   Introduction
Top
 Abstract
 Introduction
Patients and Methods
 Results
 Discussion
 References
 
Breast cancer presents a serious public health risk in both developed and developing countries. With 1 million new cases diagnosed in the world annually, it accounts for 18% of all female malignancies (1, 2). Risk factors for this disease vary from lifestyle to genetic factors (3), which are estimated to account for 15% to 25% of the cases (4). Germ line mutations in high-penetrance genes, such as BRCA 1 and BRCA 2, explain <5% of all breast cancer cases (4). Most likely, the genetic susceptibility to breast cancer is explained by multiple highly penetrant mutations and a larger number of low penetrance mutations (5). The genes involved in breast cancer are expected to be responsible for key processes in cell growth regulation and cell proliferation, including angiogenesis (6). One of the newly studied angiogenic and growth factors is angiotensin II (7), which has a wide spectrum of target tissues, including breast epithelial cells. It has a variety of functions, acting as a growth factor both in normal and cancer epithelial breast cells and promoting angiogenesis (7, 8). Angiotensin II is converted from angiotensin I by the angiotensin-converting enzyme (ACE). Studies conducted to assess the role of ACE and ACE inhibitors in both breast cancer and cancer in general show contradicting results. Whereas ACE inhibitors have been shown to block the processes of angiogenesis and tumor growth both in vivo and in vitro (9, 10), findings on the protective effect of ACE inhibitors on cancer still remain inconsistent. Whereas Lever et al. (11) found a decreased risk of cancer in patients taking ACE inhibitors, Li et al. (12) and Friis et al. (13) showed no protective effect of these drugs. An alternative way to study the role of ACE in cancer is to study the gene encoding for this enzyme. The ACE gene, which is located in chromosome 17q23, has many polymorphisms. The most commonly studied is a 287 bp Alu insertion/deletion (I/D) polymorphism in intron 16 that accounts for 50% of the variability in circulating ACE levels (14-16) and has been shown to be in complete linkage disequilibrium with the putative ACE-linked quantitative trait locus in Caucasians (15, 16). Furthermore, Koh et al. (17) showed that Chinese women who carried the I allele of the ACE I/D polymorphism had lower risk of developing breast cancer.

In this study, we evaluated the relationship of the I/D polymorphism in the ACE gene to breast cancer risk in a population-based study of Caucasian postmenopausal women.


   Patients and Methods
Top
 Abstract
 Introduction
 Patients and Methods
Results
 Discussion
 References
 
Study Population
Our study is part of the Rotterdam Study, a population-based follow-up study of determinants of diseases in the elderly. All inhabitants of Ommoord, a suburb of Rotterdam, ages 55 years or older were invited to participate, of whom 7,983 agreed (78.1%). The design of the study has been previously described (18). Informed consent was obtained from all subjects, and the Medical Ethics Committee of the Erasmus Medical Center approved the study. The study population consisted of all 4,878 female postmenopausal participants.

Measurements
At baseline, information concerning age, smoking behavior, parity and number of children, hormone replacement therapy, age at menopause, and medical history was obtained by an interview (18). Body mass index (BMI) was calculated by dividing the weight in kilograms by the height (in meters) squared (19). Blood pressure measurement has been previously described (20).

Cancer Diagnosis
General practitioners reported the cases through a computer system covering 80% of the study population. For those participants not covered, research physicians visit general practitioners to record all morbidity. Finally, to acquire a complete ascertainment, histologically confirmed breast cancer diagnoses and incidence dates were obtained from the discharge registries of all hospitals in Rotterdam, the Daniel den Hoed cancer clinic, and Pathological Anatomical District Automatized Archives (21), a Dutch nationwide network and registry of histopathology and cytopathology. Furthermore, a biannual screening mammography was implemented in 1991 for women ages 50 to 69 years and since 1998 also for women 70 to 74 years (22). All diagnoses until February 2003, both in situ and invasive carcinomas, were included in the analyses.

Genotyping
The ACE I/D polymorphism was genotyped in 4,117 (89.4%) of the women in the Rotterdam Study (84.4%). DNA was isolated from blood samples using standard procedures (salting out method; ref. 23). The II, ID, and DD genotypes were detected by using the PCR technique according to the method of Lindpainter et al. (24) with modifications. The genotype procedure has been already described (25).

Data Analysis
Hardy-Weinberg equilibrium of the I/D polymorphism was tested using Markov-Chain Monte-Carlo approximation of the exact test, as implemented in the GENEPOP package V 3.3 (26). Categorical variables (parity, hormone replacement therapy, smoking, antihypertensive drug use, and ACE inhibitors use) were compared between genotype groups using the {chi}2 test. Continuous variables, which were not normally distributed (age at entry, age at menopause, and BMI), were compared using the independent-sample Mann-Whitney test. We conducted the analysis in two steps. First, we used logistic regression to study the risk of breast cancer by ACE genotype. We adjusted for possible confounders, such as age at entry and age at menopause, and we stratified for parity, hormone replacement therapy, smoking, antihypertensive drug use, and BMI, generating five models. Second, and to calculate disease-free survival by ACE genotype, a Cox proportional hazards model was fitted using age as the underlying time of the model and taking the II genotype as the reference category. Further stratification was done by parity, hormone replacement therapy, and BMI to study interactions between the gene and other risk factors associated with breast cancer. The covariates used in both analyses were used because of their well-documented importance as risk factors for breast cancer (11, 12, 27-29) or their association with genotype (20, 25). Logistic regression analysis was done using SPSS for Windows software package version 11.0 and the survival analyses were carried out using the S-plus program version 6.


   Results
Top
 Abstract
 Introduction
 Patients and Methods
 Results
Discussion
 References
 
Of a total of 4,878 postmenopausal women included in our study, 4,117 (84.4%) were successfully genotyped. Of these women, 8.1% were lost to follow-up. Loss of follow-up was not associated with ACE genotype or to risk factors for breast cancer. The frequencies of the I/D genotypes of the ACE gene were in Hardy-Weinberg equilibrium proportions (P = 0.96). The distribution of the studied variables was not significantly different between genotypes (Table 1). The distribution of ACE inhibitors use between genotypes was not different across genotypes (data not shown).


View this table:
[in this window]
[in a new window]
  		Table 1. General characteristics of the study population stratified by ACE I/D genotype

 
There were 87 (2.1%) women who entered the study with previously diagnosed breast cancer and 114 (3.4%) were diagnosed during follow-up. The prevalent cases were excluded from all analyses. The number of breast cancer cases by genotype is shown in Fig. 1. The figure shows that the number of breast cancer patients increases as the number of D alleles increases (Ptrend = 0.02).



View larger version (11K):
[in this window]
[in a new window]
  		Figure 1. Frequency of breast cancer cases by genotype.

 
The logistic regression yielded an odds ratio (OR) of 1.86 [95% confidence interval (95% CI), 1.06-3.27; P = 0.03] for DD carriers. Further adjustment of this model for hormone replacement therapy produced the same results. Adjustment for antihypertensive drug use provided an OR of 1.90 (95% CI, 1.06-3.27; P = 0.3) for DD versus II carriers. This association remained significant when additionally adjusting for parity (OR, 1.79; 95% CI, 1.06-3.27; P value = 0.03), smoking (OR, 1.83; 95% CI, 1.04-3.21; P = 0.03), and BMI (OR, 2.06; 95% CI, 1.14-3.71, P = 0.02).

Hazard ratios for breast cancer risk for the DD and ID genotypes are shown in Table 2. In our first model, we used age as the underlying time of the model and adjusted for age at menopause. By age 90 years, 4% of the DD carriers had developed breast cancer compared with 2.3% of II carriers and 2.8% of ID carriers. This translates into a hazard ratio for breast cancer of 1.80 (95% CI, 1.07-3.01; P = 0.026) for DD, which is maintained at all ages (Fig. 2).


View this table:
[in this window]
[in a new window]
  		Table 2. Hazard ratios for breast cancer by genotype

 


View larger version (10K):
[in this window]
[in a new window]
  		Figure 2. Cancer-free survival by ACE I/D polymorphism.

 

   Discussion
Top
 Abstract
 Introduction
 Patients and Methods
 Results
 Discussion
References
 
We conducted an association study to evaluate the relationship between the ACE I/D polymorphism and the risk of breast cancer, and we did so in two steps. Our analysis showed that DD carriers have an increased risk of developing breast cancer. When analyzing this group, all further adjusted models showed significantly increased risks for DD carriers when compared with II carriers. We also report a linear increase of breast cancer risk with the presence of the D allele of I/D polymorphism in the ACE gene.

For premenopausal women, the BRCA 1 and BRCA 2 genes have been associated with an increased risk for breast cancer (5, 27, 30-32). A vast literature suggests that variants in genes that regulate cell growth are involved in the development of this disease (5, 33). Moreover, several studies have shown that angiotensin II acts as a growth factor in normal and breast cancer cells through phospholipase C activation (8, 34-37). Koh et al. (17) conducted a study among Chinese postmenopausal women in which they found that individuals carrying the II genotype had a significantly reduced risk of breast cancer independently of environmental and other familial risk factors for the disease. On the other hand, Haiman et al. (38) did a case-control study in a multiethnic cohort where they observed a modest positive association between the II genotype and breast cancer risk in African Americans. They did not, however, see the association consistently in all ethnic groups. Furthermore, although they had a large sample within each ethnic group, it was not large enough to evaluate ethnic specific risks, and their patients included both premenopausal and postmenopausal women.

A large number of polymorphisms are known in the ACE gene. Here, we only tested the ACE I/D polymorphism in intro 16. It has been previously reported that in a subset of our population, this polymorphism explains around 28% of the variability of plasma ACE levels (39). Furthermore, this polymorphism is in strong linkage disequilibrium with the functional ones in this gene, as measured as the relation to ACE levels or cardiovascular disease outcomes (15, 16). The strong linkage disequilibrium implies that testing additional markers will yield little extra information.

Thus far, and to our knowledge, no follow-up study has been done to assess breast cancer–free survival by ACE I/D genotype. Our study is the first to investigate the risk of breast cancer longitudinally, and find that it was significantly increased in DD versus II carriers independently of all our proposed known risk factors. Hormone replacement therapy and parity did not weaken our association between the I/D polymorphism and breast cancer risk.

Our results suggest that the ACE I/D polymorphism may play an important role as susceptibility factor in breast cancer risk and disease-free survival in Caucasian postmenopausal women.


   Acknowledgments
 
We thank Frank van Rooij for help in the writing process of this paper.


   Footnotes
 
Grant support: The Netherlands Organization for Scientific Research grant 904-61-196, EUR Fellowship (O. Njajou), and Centre of Medical Systems Biology grant 297-2003 (A. Arias Vasquez). The Rotterdam Study is supported by the Erasmus Medical Center and Erasmus University Rotterdam; the Netherlands Organization for Scientific Research; the Netherlands Organization for Health Research and Development; Research Institute for Diseases in the Elderly; Ministry of Education, Culture and Science; Ministry of Health, Welfare, and Sports; European Commission (DG XII); and Municipality of Rotterdam.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: A. Arias Vásquez contributed with the design of the study and also participated in the data analyses along with F.A. Sayer-Tabatabaei and C. van Duijn, who participated in the design and writing of the manuscript. J.W. Coebergh, B. Stricker, and A. Hofman aided in the data collection and the writing of the manuscript as well.

Received 1/18/05; revised 6/15/05; accepted 6/22/05.


   References
Top
 Abstract
 Introduction
 Patients and Methods
 Results
 Discussion
 References
 

  1. Perera NM, Gui GP. Multi-ethnic differences in breast cancer: current concepts and future directions. Int J Cancer 2003;106:463–7.[CrossRef][Medline]
  2. Prichard RS, Hill AD, Dijkstra B, et al. The prevention of breast cancer. Br J Surg 2003;90:772–83.[Medline]
  3. Singletary SE. Rating the risk factors for breast cancer. Ann Surg 2003;237:474–82.[CrossRef][Medline]
  4. Mitrunen K, Hirvonen A. Molecular epidemiology of sporadic breast cancer. The role of polymorphic genes involved in oestrogen biosynthesis and metabolism. Mutat Res 2003;544:9–41.[CrossRef][Medline]
  5. Nathanson KL, Wooster R, Weber BL, et al. Breast cancer genetics: what we know and what we need. Nat Med 2001;7:552–6.[CrossRef][Medline]
  6. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992;267:10931–4.[Free Full Text]
  7. Walther T, Menrad A, Orzechowski HD, et al. Differential regulation of in vivo angiogenesis by angiotensin II receptors. FASEB J 2003;17:2061–7.[Abstract/Free Full Text]
  8. Greco S, Muscella A, Elia MG, et al. Activation of angiotensin II type I receptor promotes protein kinase C translocation and cell proliferation in human cultured breast epithelial cells. J Endocrinol 2002;174:205–14.[Abstract]
  9. Fujita M, Hayashi I, Yamashina S, et al. Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. Biochem Biophys Res Commun 2002;294:441–7.[CrossRef][Medline]
  10. Volpert OV, Ward WF, Lingen MW, et al. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 1996;98:671–9.[Medline]
  11. Lever AF, Hole DJ, Gillis CR, et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 1998;352:179–84.[CrossRef][Medline]
  12. Li CI, Malone KE, Weiss NS, et al. Relation between use of antihypertensive medications and risk of breast carcinoma among women ages 65-79 years. Cancer 2003;98:1504–13.[Medline]
  13. Friis S, Sorensen HT, Mellemkjaer L, et al. Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark. Cancer 2001;92:2462–70.[CrossRef][Medline]
  14. Tiret L, Rigat B, Visvikis S, et al. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet 1992;51:197–205.[Medline]
  15. Keavney B, McKenzie CA, Connell JM, et al. Measured haplotype analysis of the angiotensin-I converting enzyme gene. Hum Mol Genet 1998;7:1745–51.[Abstract/Free Full Text]
  16. McKenzie CA, Abecasis GR, Keavney B, et al. Trans-ethnic fine mapping of a quantitative trait locus for circulating angiotensin I-converting enzyme (ACE). Hum Mol Genet 2001;10:1077–84.[Abstract/Free Full Text]
  17. Koh WP, Yuan JM, Sun CL, et al. Angiotensin I-converting enzyme (ACE) gene polymorphism and breast cancer risk among Chinese women in Singapore. Cancer Res 2003;63:573–8.[Abstract/Free Full Text]
  18. Hofman A, Grobbee DE, de Jong PT, et al. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol 1991;7:403–22.[CrossRef][Medline]
  19. Garrow J. Quetelet index as indicator of obesity. Lancet 1986;1:1219.
  20. Schut AF, Sayed-Tabatabaei FA, Witteman JC, et al. Smoking-dependent effects of the angiotensin-converting enzyme gene insertion/deletion polymorphism on blood pressure. J Hypertens 2004;22:313–9.[CrossRef][Medline]
  21. Bijlsma F, van der Esch EP. [PALGA, of labor pains of the Pathological Anatomical District Automatized Archives] [Article in Dutch] PALGA, of de barensweeen van een Pathologisch Anatomisch Landelijk Geautomatiseerd Archief. Ned Tijdschr Geneeskd 1972;116:902–3.[Medline]
  22. de Koning HJ, van Ineveld BM, van Oortmarssen GJ, et al. Breast cancer screening and cost-effectiveness; policy alternatives, quality of life considerations and the possible impact of uncertain factors. Int J Cancer 1991;49:531–7.[Medline]
  23. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.[Free Full Text]
  24. Lindpaintner K, Pfeffer MA, Kreutz R, et al. A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med 1995;332:706–11.[Abstract/Free Full Text]
  25. Sayed-Tabatabaei FA, Schut AF, Hofman A, et al. A study of gene-environment interaction on the gene for angiotensin converting enzyme: a combined functional and population based approach. J Med Genet 2004;41:99–103.[Abstract/Free Full Text]
  26. Raymond M, Rousset F. Genepop (version 1.2): population genetics software for exact tests and ecumenism. J Heredity 1986;86:248–9.
  27. Bernstein L. Ethnicity-related variation in breast cancer risk factors. Cancer 2002;97:222–9.
  28. DeBruin L. Perspectives on the chemical etiology of breast cancer. Environ Health Perspect 2002;110:119–28.
  29. Lahmann PH, Hoffmann K, Allen N, et al. Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 2004;111:762–71.[CrossRef][Medline]
  30. Welcsh PL, King MC. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet 2001;10:705–13.[Abstract/Free Full Text]
  31. Monteiro AN. BRCA1: the enigma of tissue-specific tumor development. Trends Genet 2003;19:312–5.[CrossRef][Medline]
  32. Mincey BA. Genetics and the management of women at high risk for breast cancer. Oncologist 2003;8:466–73.[Abstract/Free Full Text]
  33. McKelvey KD, Jr., Evans JP. Cancer genetics in primary care. J Nutr 2003;133:3767–72S.
  34. Greco S, Muscella A, Elia MG, et al. Angiotensin II activates extracellular signal regulated kinases via protein kinase C and epidermal growth factor receptor in breast cancer cells. J Cell Physiol 2003;196:370–7.[CrossRef][Medline]
  35. Muscella A, Greco S, Elia MG, et al. Angiotensin II stimulation of Na+/K+ATPase activity and cell growth by calcium-independent pathway in MCF-7 breast cancer cells. J Endocrinol 2002;173:315–23.[Abstract]
  36. De Paepe B, Verstraeten VL, De Potter CR, et al. Growth stimulatory angiotensin II type-1 receptor is upregulated in breast hyperplasia and in situ carcinoma but not in invasive carcinoma. Histochem Cell Biol 2001;116:247–54.[Medline]
  37. De Paepe B, Verstraeten VM, De Potter CR, et al. Increased angiotensin II type-2 receptor density in hyperplasia, DCIS and invasive carcinoma of the breast is paralleled with increased iNOS expression. Histochem Cell Biol 2002;117:13–9.[CrossRef][Medline]
  38. Haiman CA, Henderson SO, Bretsky P, et al. Genetic variation in angiotensin I-converting enzyme (ACE) and breast cancer risk: the multiethnic cohort. Cancer Res 2003;63:6984–7.[Abstract/Free Full Text]
  39. Sayed-Tabatabaei FA, Houwing-Duistermaat JJ, van Duijn CM, et al. Angiotensin-converting enzyme gene polymorphism and carotid artery wall thickness: a meta-analysis. Stroke 2003;34:1634–9.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
M. Sugimoto, T. Furuta, N. Shirai, M. Ikuma, H. Sugimura, and A. Hishida
Influences of chymase and Angiotensin I-converting enzyme gene polymorphisms on gastric cancer risks in Japan.
Cancer Epidemiol. Biomarkers Prev., October 1, 2006; 15(10): 1929 - 1934.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by González-Zuloeta Ladd, A. M.
Right arrow Articles by van Duijn, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by González-Zuloeta Ladd, A. M.
Right arrow Articles by van Duijn, C.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation